Affimed NV (AFMD) was Downgraded by Leerink Partners to ” Mkt Perform”. Earlier the firm had a rating of “Outperform ” on the company shares. Leerink Partners advised their investors in a research report released on Aug 12, 2016.
Many Wall Street Analysts have commented on Affimed NV. Affimed NV was Downgraded by Leerink Partners to ” Mkt Perform” on May 19, 2016.
On the company’s financial health, Affimed NV reported $-0.24 EPS for the quarter, missing the analyst consensus estimate by $ -0.03 based on the information available during the earnings call on Aug 10, 2016. Analyst had a consensus of $-0.21. The company had revenue of $2.07 million for the quarter, compared to analysts expectations of $1.43 million. The company’s revenue was down -6.4 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.19 EPS.
Affimed NV closed down -0.04 points or -1.25% at $3.16 with 65,780 shares getting traded on Monday. Post opening the session at $3.2, the shares hit an intraday low of $3.09 and an intraday high of $3.23 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
Affimed N.V. (Affimed) is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company’s research and development pipeline consists of AFM13 AFM11 AFM21 TandAb and Trispecific Ab. The Company’s lead candidate AFM13 is a NK-cell TandAb designed for the treatment of certain CD30-positive (CD30+) B- and T-cell malignancies including Hodgkin Lymphoma or HL. AFM11 is a T-cell TandAb designed for the treatment of certain CD19+ B-cell malignancies including non-Hodgkin Lymphoma or NHL Acute Lymphocytic Leukemia or ALL and Chronic Lymphocytic Leukemia or CLL. AFM21 selectively binds Epidermal Growth Factor Receptor variant III or EGFRvIII. The Company’s TandAbs brings NK-cells or T-cells into proximity and triggers a signal cascade that leads to the destruction of cancer cells.